prednisone

P2, N=100, Recruiting, University of Washington | Trial completion date: Jul 2031 --> Jul 2033 | Trial primary completion date: Jul 2026 --> Jul 2028

P2, N=39, Active, not recruiting, University of Rochester | Recruiting --> Active, not recruiting

Despite partial responses to topical therapies, oral prednisone, and methotrexate, the disease persisted, highlighting therapeutic challenges. This case underscores the importance of molecular profiling in PCAECTCL and suggests potential utility for JAK inhibitors like ruxolitinib.

P1/2, N=35, Recruiting, Prevail Therapeutics | Trial primary completion date: Apr 2030 --> Apr 2031 | Trial completion date: Apr 2030 --> Apr 2031

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) induction achieved morphological complete remission, but measurable residual disease (MRD) persisted. Consolidation with mini-cyclophosphamide, vincristine, and dexamethasone (mini-CVD) and prednisone, vincristine, methotrexate, and 6-mercaptopurine (POMP) maintenance failed to eradicate MRD, and overt relapse occurred at month 7. Nelarabine salvage was initiated...Early molecular risk stratification and deployment of targeted agents, venetoclax-based combinations, or timely allogeneic transplantation should be considered before irreversible genomic complexity emerges. Prospective studies tailored to high-risk cytogenetic subsets of MPAL are urgently needed.

Initial therapy comprised high-dose methylprednisolone, intravenous immunoglobulin and thalidomide, followed by surgical resection and adjuvant thalidomide-cyclophosphamide-prednisone. Postoperatively, inflammatory indices normalized and mucocutaneous lesions partially improved; nevertheless, the patient died of respiratory failure 6 months after surgery. In summary, the present case report aimed to provide valuable references and experiences for clinicians in the diagnosis and treatment of CD featuring PNP and FDCS.

In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation.

P3, N=800, Not yet recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2029

This case suggests a potential association between LCA and PNH. Splenectomy provided dual benefits by treating the splenic tumor and improving hemolysis. Given the possible risk of malignant transformation, long-term follow-up is recommended.

P2, N=152, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting

P2, N=32, Completed, University Hospital, Lille | Unknown status --> Completed | N=80 --> 32

This study aimed to determine whether genetic variants in key effector molecules influence treatment outcomes in aggressive B-cell non-Hodgkin lymphoma (B-NHL).We genotyped variants of PRF A91V (rs35947132), GZMB Q48R (rs8192917), and FASL (rs5030772 and rs763110) in 501 patients from the RICOVER-60 trial (NCT0052936/EU-20243), which compared 6 versus 8 cycles of chemotherapy containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without rituximab in elderly patients with untreated aggressive B-NHL. Carriers showed significantly better outcomes with CHOP alone but no additional benefit from rituximab. These findings were validated in independent cohorts of aggressive B-NHL but not in CLL, where the PRF1 A91V variant was overrepresented (119/589; 20%) compared to aggressive B-NHL and general population.Our results suggest that PRF A91V is a negative predictive marker for rituximab-mediated cellular cytotoxicity in aggressive B-NHL and may have broader implications for immune effector cell-based therapies.